Trials / Recruiting
RecruitingNCT06104553
A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma
A Phase Ib/II Study of SHR-A1912 Combined With Other Therapies in Patients With B-cell Non-Hodgkin 's Lymphoma
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 132 (estimated)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the safety, PK and preliminary anti-tumour activity of SHR-A1912 combined with other therapies in patients with B-cell non-Hodgkin 's lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A1912; R-Chemo | SHR-A1912 combined with R-Chemo: SHR-A1912 + R-Chemo (Rituximab + Chemotherapy) (Phase 1b) |
| DRUG | SHR-A1912; R-Chemo | SHR-A1912 combined with R-Chemo: SHR-A1912 (RP2D) + R-Chemo (Rituximab + Chemotherapy) (Phase 2) |
Timeline
- Start date
- 2023-11-17
- Primary completion
- 2025-12-01
- Completion
- 2026-06-01
- First posted
- 2023-10-27
- Last updated
- 2023-12-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06104553. Inclusion in this directory is not an endorsement.